STOCK TITAN

Alkermes plc. (ALKS) SEC Filings

ALKS NASDAQ

Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.

Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.

Rhea-AI Summary

Alkermes plc said its wholly owned indirect subsidiaries, Alkermes, Inc. and Alkermes Pharma Ireland Limited, entered into a confidential settlement and license agreement with Teva Pharmaceuticals, Inc. concerning a lawsuit about certain U.S. patents for all dosage strengths of LYBALVI. The agreement grants Teva a limited, non-exclusive, royalty-free, non-transferable and non-sublicensable license to make, have made, use, import, sell and offer for sale products made under its ANDA in the United States beginning November 12, 2039, or, if Alkermes obtains pediatric exclusivity, May 12, 2040, or earlier under certain circumstances.

The parties filed a joint Stipulation of Dismissal with Prejudice on November 9, 2026, to dismiss the pending proceedings. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.90%
Tags
current report
-
Rhea-AI Summary

Alkermes plc. reported a sale by David Joseph Gaffin, EVP, CLO of Alkermes, Inc.: 2,035 Ordinary Shares at $46.17 per share on November 3, 2026. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2025. Gaffin directly held 219,353 shares after the transaction. The transaction description characterizes it as a sale in the open market or a private transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
insider
-
Rhea-AI Summary

Alkermes plc. (ALKS) officer David Joseph Gaffin gave notice of a proposed sale of 2,035 common shares, with an aggregate market value of $93,955.95. The notice lists Merrill Lynch as broker, November 3, 2026, as the approximate sale date, and NASDAQ as the exchange. It also reports five prior sales of 2,034 shares each between June 4, 2026, and October 2, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
other
Rhea-AI Summary

Alkermes plc (ALKS) reported third-quarter 2026 revenue of $480.132 million, up from $394.185 million a year earlier, while net income was $16.287 million versus $82.761 million. For the first nine months, revenue totaled $1,369.052 million, compared with $1,091.352 million; the company recorded a net loss of $49.692 million, compared with net income of $192.323 million. Operating cash flow for the nine months was $72.917 million, versus $350.685 million.

Alkermes completed its acquisition of Avadel Pharmaceuticals plc on February 12, 2026, adding LUMRYZ. Preliminary purchase consideration was $2,306.920 million, including $2,064.310 million in cash for Avadel shares, $134.897 million for equity awards, and $107.713 million in fair value of contingent consideration. The terms included $21.00 cash per Avadel share and a non-transferable contingent value right for a potential additional $1.50 per share upon a specified milestone. Up to $165.7 million may become due to former Avadel shareholders upon achievement of the milestone.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
quarterly report
-
Rhea-AI Summary

Alkermes plc reported third-quarter 2026 revenue of $480.1 million, compared with $394.2 million a year earlier, while GAAP net income was $16.3 million versus $82.8 million. Proprietary net sales were $417.3 million, compared with $317.4 million; LYBALVI prescriptions grew 18% from the prior-year quarter. Adjusted EBITDA, a non-GAAP measure, was $120.1 million versus $121.5 million.

For the nine months ended September 30, revenue was $1,369.1 million versus $1,091.4 million, while GAAP results were a $49.7 million net loss compared with $192.3 million net income. At September 30, cash, cash equivalents and total investments were $787.6 million. Alkermes reiterated 2026 expectations, effective only as of November 3, including revenue of $1,730–$1,840 million, GAAP net loss of $95–$115 million and adjusted EBITDA of $370–$410 million. LUMRYZ revenue was $89.9 million, with approximately 4,100 patients on therapy. The company said its 2026 results reflect the Avadel acquisition, which closed February 12, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
current report
-
Rhea-AI Summary

Alkermes plc. SVP, Chief Financial Officer Joshua Reed reported the settlement of 9,164 restricted stock units into 9,164 ordinary shares on October 8, 2026. Each unit represents a contingent right to one ordinary share, and the award vests in four equal annual installments beginning that date. On the same date, 4,069 ordinary shares were delivered or withheld for payment of exercise price or tax liability at $40.11 per share. The reported remaining balance was 27,492 restricted stock units; no Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
insider
Rhea-AI Summary

Alkermes plc. director Anne Clem Whitaker received 7,239 restricted stock units and options covering 17,998 ordinary shares on October 7, 2026. Each restricted stock unit represents a contingent right to receive one ordinary share. The options have an exercise price of $41.4450 per share and expire October 7, 2036. Both awards vest in three equal annual installments beginning October 7, 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
insider
-
Rhea-AI Summary

Alkermes plc. reports that David Joseph Gaffin, EVP, CLO of Alkermes, Inc., sold 2,034 ordinary shares on October 2, 2026, at $41.03 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted November 19, 2025. Following the sale, Gaffin directly held 221,388 ordinary shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
insider
-
Rhea-AI Summary

Alkermes plc. officer David Joseph Gaffin reported a proposed sale of 2,034 common shares through Merrill Lynch, with an aggregate market value of $83,455.02 and an approximate sale date of October 2, 2026. Gaffin also reported four prior sales of 2,034 shares each on June 4, July 6, August 3 and September 3, 2026, with gross proceeds of $87,563.70, $109,897.02, $98,811.72 and $97,652.34, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
other
Rhea-AI Summary

Alkermes plc (ALKS) reported positive topline results from a phase 1b, proof‑of‑concept study of ALKS 7290, its novel oral orexin 2 receptor agonist, in adults with attention-deficit hyperactivity disorder (ADHD). The study in healthy volunteers and 50 adults with ADHD met its primary objective of characterizing safety, tolerability, pharmacokinetics and pharmacodynamics.

In adults with ADHD, ALKS 7290 was generally well tolerated and produced dose‑dependent, clinically meaningful median reductions at day 14 on exploratory efficacy scales: 14.0 points and 19.0 points on the 54‑point AISRS for the 20 mg and 50 mg doses, and 1.0 and 2.0 point reductions on CGI‑S, indicating shifts from markedly or moderately ill to mildly ill. No serious treatment-emergent adverse events were reported, and most adverse events were mild.

The company stated that these data provide the first clinical evidence of the effects of an orexin receptor agonist in ADHD and support the dose range selected for an ongoing, well‑powered phase 2 study of ALKS 7290 in adults with ADHD, which is enrolling approximately 312 participants with data expected in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
current report

FAQ

How many Alkermes plc. (ALKS) SEC filings are available on StockTitan?

StockTitan tracks 132 SEC filings for Alkermes plc. (ALKS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Alkermes plc. (ALKS)?

The most recent SEC filing for Alkermes plc. (ALKS) was filed on November 12, 2026.